ADELAIDE, Australia,
Jan. 12, 2022 /PRNewswire/ --
Bionomics Limited (ASX:BNO, NASDAQ:BNOX) (Bionomics or Company), a
clinical-stage biopharmaceutical company, participated in the H.C
Wainwright BioConnect Conference that was held virtually from
January 10-13, 2022.
Dr Errol De Souza, Executive
Chairman of Bionomics, provided an update on the Company including
BNC210, an oral, proprietary, selective negative allosteric
modulator of the α7 nicotinic acetylcholine receptor in development
for the acute treatment of Social Anxiety Disorder (SAD) and
chronic treatment of Post-Traumatic Stress Disorder (PTSD), with
U.S. Food and Drug Administration (FDA) Fast Track designation for
both clinical indications.
The presentation is available on the Company's website
https://www.bionomics.com.au/investor-centre/presentations-posters/
FOR FURTHER INFORMATION PLEASE CONTACT:
|
General:
|
Investor
Relations:
|
|
Ms Suzanne
Irwin
|
Mr. Connor
Bernstein
|
|
Company
Secretary
|
Vice President,
Strategy and Corporate Development
|
|
+61 8 8150
7400
|
+1 (831)
246-3642
|
|
CoSec@bionomics.com.au
|
cbernstein@bionomics.com.au
|
About Bionomics Limited
Bionomics is a clinical-stage biopharmaceutical company
developing novel, allosteric ion channel modulators designed to
transform the lives of patients suffering from serious central
nervous system disorders with high unmet medical need. Bionomics is
advancing its lead product candidate, BNC210, an oral, proprietary,
selective negative allosteric modulator of the α7 nicotinic
acetylcholine receptor, for the acute treatment of Social Anxiety
Disorder and chronic treatment of Post-Traumatic Stress Disorder.
Beyond BNC210, Bionomics has a strategic partnership with Merck
& Co., Inc. (known as MSD outside the
United States and Canada)
with two drugs in early-stage clinical trials for the treatment of
cognitive deficits in Alzheimer's disease and other central nervous
system conditions.
www.bionomics.com.au
View original
content:https://www.prnewswire.com/news-releases/bionomics-limited-participated-in-the-hc-wainwright-bioconnect-conference-301459281.html
SOURCE Bionomics Limited